6 results about "Antigen variation" patented technology

The invention discloses a neutralizing swine monoclonal antibody pO18-40 and a neutralizing swine monoclonal antibody pO18-43 for foot and mouth disease virus type O. The amino acid sequences of a heavy chain variable region (VH) and a light chain variable region (VL) of the antibody pO18-40 are respectively as shown in SEQ ID No. 1 and SEQ ID No. 2; the amino acid sequences of VH and VL of the antibody pO18-43 are respectively as shown in SEQ ID No. 3 and SEQ ID No. 4. The antibody obtained by the invention is a full-swine-source antibody, can specifically neutralize the classical strain of the O-type foot-and-mouth disease virus, and can clearly distinguish the classical strain of the O / Cathay topological type from the variant strain of the O / Cathay topological type. A key antigen epitope recognized by the antibody is located at the 149th amino acid of a VP1 protein G-H ring, and the site is a key site of O / Cathay strain antigen variation and vaccine immune protection. The antibody provided by the invention provides an important tool and theoretical basis for serological detection of O-type FMDV, vaccine immune effect evaluation and optimal design of broad-spectrum vaccines.

The invention relates to the technical field of antigen prediction, and discloses an antigen prediction method which comprises the following steps: step 1, collecting an HA sequence and HI data of known virus protein; 2, carrying out data preprocessing on the HA sequence and the HI data to respectively obtain an original similarity matrix and an original antigen distance matrix; 3, performing adaptive Fourier decomposition based on a maximum selection principle to obtain an enhanced similarity matrix, and constructing a preset model based on PDM and MLP; 4, performing down-sampling processing on the enhanced similarity matrix to obtain a similarity matrix of the three scale windows; 5, performing multi-scale mixing on the similarity matrixes of the three scale windows to obtain a fused similarity matrix, and training a PDM module in a preset model; 6, training an MLP module in a preset model according to the fusion similarity matrix and the original antigen distance matrix to obtain an antigen variation prediction model; and 7, outputting the antigen distance of the virus to be analyzed by the antigen variation prediction model.

Provided is a method for producing an influenza HA split vaccine which produces an antibody that binds to an HA stem region of influenza, the HA stem region being less likely to cause antigenic variation, An influenza HA split vaccine is subjected to an acidic treatment. Through the acidic treatment, an influenza HA split vaccine which produces an antibody that binds to an LAH of the HA stem region is obtained. This influenza HA split vaccine has an excellent ability against infection of other influenza viruses of different antigenicity.

Provided is a method for producing an influenza HA split vaccine, which generates antibodies that bind to the stem region of the HA of influenza, wherein the stem region of the HA is difficult to generate antigenic variation. The influenza HA split vaccine is subjected to acidic treatment. By performing the acidic treatment, an influenza HA split vaccine is obtained, which generates antibodies that bind to the stem region of the HA. This influenza HA split vaccine has good protection against infection by other influenza viruses having different antigenicity.

This invention discloses a Mycoplasma caprineis subspecies Mccp NM strain and its applications. Whole-genome alignment of this strain revealed 422 missense mutations, 132 frameshift mutations, and several key insertion / deletion variations compared to the existing vaccine strain C87001. In virulence studies, at a concentration of 1×10⁻⁶... 9 In healthy, susceptible goats, intratracheal injection at a CCU / mL dose resulted in all experimental goats exhibiting typical symptoms of caprine contagious pleuropneumonia. Autopsy revealed pleural effusion and liver-like lesions in the lungs. The inactivated vaccine prepared using this strain demonstrated good safety in goats. Challenge protection tests showed that the vaccine of this invention provided 100% protection against homologous challenge with the NM strain and 80% protection against the heterologous C87002 strain, while commercially available vaccines offered only 40% protection against the NM strain. This invention overcomes the deficiency of existing vaccines in providing insufficient protection against clinical variants, offering an effective technical reserve and candidate vaccine for addressing immunization failure caused by Mccp antigen mutations.

The invention provides a multi-drug-resistant acinetobacter baumannii recombinant vesicular subunit vaccine and application thereof. The subunit vaccine takes an acinetobacter baumannii bilayer membrane vesicle (BBV) as a delivery carrier and a self-adjuvant; the surface of the double-layer membrane vesicle of the acinetobacter baumannii is loaded with three antigen components: an outer membrane protein A (OmpA) of the acinetobacter baumannii, an outer membrane protein W (OmpW) of the acinetobacter baumannii and an outer membrane protein 22 (Omp22) of the acinetobacter baumannii. According to the invention, the limitation of the traditional single target vaccine is broken through, the BBV is used for providing a membrane-related antigen, three core outer membrane proteins of OmpA, Omp22 and OmpW are combined, and pathogenic key links such as multi-dimensional targeting bacterial adhesion, biomembrane formation, drug resistance and the like are realized. On the basis of the natural strain adaptability of the BBV and the high conservative property of the three proteins, the antibody generated through induction after vaccine immunization can be subjected to cross recognition with at least 10 different serotype multi-drug-resistant strains, the protection range is greatly widened, and the problem that an existing vaccine is prone to failure due to antigen variation is solved.